Skip to main content
SpringerLink
Log in

MicroRNAs: Role in Cancer and miRNA Signatures in Endometrial Cancer

  • Chapter
  • First Online:
Recent Advances in Endometrial Cancer

  • 350 Accesses

Abstract

Endometrial cancer is a common malignant gynecological tumor with approximately 3% of women diagnosed with EC at some point in their lifetime. There are only a few biomarkers that are useful in early diagnosis of the disease and guiding treatment principles. MicroRNAs which are 19–23 base pair long functional transcripts that regulate gene expression by cleavage or translational suppression of target mRNA may help in effective and minimally invasive diagnosis and in planning treatment strategies. Widespread differential expressions of miRNA genes in malignant tissues across many cancer types compared to normal tissues are now well documented. Herein, we describe the role of miRNAs in cancer development and discuss how their genomic interaction will impact both research and clinical management for endometrial cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  2. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jønsson L, Eriksen PS, Ottesen B. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol. 2000;182(1):23–9.

    CAS  PubMed  Google Scholar 

  3. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783.

    CAS  PubMed  Google Scholar 

  4. Rizzuto I, Nicholson R, MacNab WS, Nalam M, Sharma R, Rufford B. Risk factors and sonographic endometrial thickness as predictors of tumour stage and histological subtype of endometrial cancer. Gynecol Oncol Rep. 2019;30:100491.

    PubMed  PubMed Central  Google Scholar 

  5. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111(1):82–8.

    PubMed  Google Scholar 

  6. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    CAS  PubMed  Google Scholar 

  7. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843–54.

    Google Scholar 

  8. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. 2003; RNA 9:175–9.

    Google Scholar 

  9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Hannafon BN, Ding W-Q. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14:14240–69. https://doi.org/10.3390/ijms140714240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wang X, Zhao X, Gao P, Wu M. c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Sci Rep. 2013; 3:1942.

    Google Scholar 

  13. Allegra D, Bilan V, Garding A, Döhner H, Stilgenbauer S, Kuchenbauer F, Mertens D. Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia. 2014;28(1):98.

    CAS  PubMed  Google Scholar 

  14. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22. https://doi.org/10.1038/nrd.2016.246. Published online 17 Feb 2017.

  15. Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6(6):567–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104(40):15805–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Kim DH, Sætrom P, Snøve O, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA. 2008;105(42):16230–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA. 2008;105(5):1608–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther. 2001;296(3):890–7.

    CAS  PubMed  Google Scholar 

  20. Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L, Wang B, Ye G, Xiao B, Guo J. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumor Biol. 2015;36(3):2007–12.

    Google Scholar 

  21. Delangle R, De Foucher T, Larsen AK, Sabbah M, Azaïs H, Bendifallah S, Daraï E, Ballester M, Mehats C, Uzan C, Canlorbe G. The use of microRNAs in the management of endometrial cancer: a meta-analysis. Cancers. 2019;11(6):832.

    CAS  PubMed Central  Google Scholar 

  22. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012;12(1):369.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008;110(2):206–15.

    CAS  PubMed  Google Scholar 

  24. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009;18(1):50–5.

    CAS  PubMed  Google Scholar 

  25. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009;124(6):1358–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Mozos A, Catasús L, D’Angelo E, Serrano E, Espinosa I, Ferrer I, Pons C, Prat J. The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. Hum Pathol. 2014;45(5):942–51.

    CAS  PubMed  Google Scholar 

  27. Dai Y, Xia W, Song T, Su X, Li J, Li S, Chen Y, Wang W, Ding H, Liu X, Li H. MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells. Nucleic Acid Ther. 2013;23(1):29–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hiroki E, Suzuki F, Akahira JI, Nagase S, Ito K, Sugawara JI, Miki Y, Suzuki T, Sasano H, Yaegashi N. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer. 2012;131(4):e395–404.

    CAS  PubMed  Google Scholar 

  29. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Susumu N, Aoki D. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics. 2012;4(2):147–62.

    CAS  PubMed  Google Scholar 

  30. Liu P, Qi M, Ma C, Lao G, Liu Y, Liu Y, Liu Y. Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B. FEBS Lett. 2013;587(16):2523–9.

    CAS  PubMed  Google Scholar 

  31. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130(5):1036–45.

    CAS  PubMed  Google Scholar 

  32. Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J, Hu Y. microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep. 2012;27(3):807–12.

    CAS  PubMed  Google Scholar 

  33. Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, Zhou H, Xun Q. Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS One. 2014;9(3):e90810.

    PubMed  PubMed Central  Google Scholar 

  34. Tan ZQ, Liu FX, Tang HL, Su Q. Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer. Zhonghua fu chan ke za zhi. 2010;45(10):772–4.

    CAS  PubMed  Google Scholar 

  35. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, Zheng XL. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(6):2084–92.

    CAS  PubMed  Google Scholar 

  36. Montagnana M, Benati M, Danese E, Giuidici S, Perfranceschi M. Aberrant microRNA expression in patients with endometrial cancer. Int J Gynecol Cancer. 2017;27:459–66.

    PubMed  Google Scholar 

  37. Shang C, Lu YM, Meng LR. MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit. 2012;18(4):BR149.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomarker Res. 2013;1(1):12.

    Google Scholar 

  39. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 2011;10(1):99.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLoS One 2014;9(4):e94167.

    Google Scholar 

  41. Hiroki E, Akahira JI, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2010;101(1):241–9.

    CAS  PubMed  Google Scholar 

  42. Tsuruta T, Kozaki KI, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011;71(20):6450–62.

    CAS  PubMed  Google Scholar 

  43. Jiang L, Meng W, Zeng J, Hu H, Lu L. MiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis. Cell Biol Int. 2013;37(6):577–83.

    CAS  PubMed  Google Scholar 

  44. Shen Y, Lu L, Xu J, Meng W, Qing Y, Liu Y, Zhang B, Hu H. Bortezomib induces apoptosis of endometrial cancer cells through micro RNA-17-5p by targeting p21. Cell Biol Int. 2013;37(10):1114–21.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Genetics and Biochemistry, Indian Council of Medical Research (ICMR), National Institute of Cancer Prevention and Research, Noida, Uttar Pradesh, India

    Heena Gautam, Manikankana Bandopadhyay & Mausumi Bharadwaj

  2. Department of Obstetrics & Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

Authors
  1. Heena Gautam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manikankana Bandopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sumita Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mausumi Bharadwaj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mausumi Bharadwaj .

Editor information

Editors and Affiliations

  1. Department of Obstetrics & Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Obstetrics and Gynecology, UCMS & GTB Hospital, Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gautam, H., Bandopadhyay, M., Mehta, S., Bharadwaj, M. (2020). MicroRNAs: Role in Cancer and miRNA Signatures in Endometrial Cancer. In: Mehta, S., Gupta, B. (eds) Recent Advances in Endometrial Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-15-5317-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-5317-2_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-5316-5

  • Online ISBN: 978-981-15-5317-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation